Operating profit EBITDA: arcutis.com (ARQT)

Brandmark of Arcutis Biotherapeutics, Inc. (ARQT)

Arcutis Biotherapeutics (ARQT) retains patients due to the chronic nature of skin pathologies within the non-steroidal ecosystem. The issuer is developing unique non-hormonal treatments for eczema, aiming for leadership in dermatology. Strict FDA oversight and patent protection limit the entry of new players. The company's EBITDA statistics demonstrate real demand, where the 37.96 level reflects the status of the operating profit parameter.

Profit before payment of interest, taxes and amortization: arcutis.com (ARQT) for 11/23/2025 - 11/14/2026

Summary analytical data breakdowns for Arcutis Biotherapeutics, Inc. (ARQT)

- stock value and consensus price forecast:
Market Chart Arcutis Corp|ARQT - Price Target Chart
- company stock exchange capitalization indicators:
Market Capitalization Arcutis Biotherapeutics|ARQT - Enterprise Value
- book value of equity indicators:
Net Assets per Share Arcutis Biotherapeutics|ARQT - Company Book Value|Capitalization to Book Value Ratio arcutis.com|ARQT - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Capital Arcutis Biotherapeutics|ARQT - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Arcutis|ARQT - Company Aggregate Debts|Debt to Book Value Arcutis Biotherapeutics|ARQT - Company Long-Term Liabilities|Company Short-Term Debts Arcutis Biotherapeutics|Intermediate Liquidity Ratio arcutis.com
- company profitability and valuation multiples indicators:
ARQT - Net Profit|Company Profit Forecast Arcutis Biotherapeutics|ARQT - Price to Earnings Ratio|Market Cap to Projected Earnings arcutis.com|ARQT - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Arcutis Biotherapeutics|ARQT - Operating profit EBITDA|Earnings per share for the last twelve months Arcutis Biotherapeutics|ARQT - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months arcutis.com|ARQT - Earnings per share growth in current year|Expected net earnings per share growth next year Arcutis Biotherapeutics
- sales and revenue data:
ARQT - Company Sales|Company Projected Revenue Volume Arcutis Corp|ARQT - P/S Multiple|Forward Price to Sales Arcutis Biotherapeutics
Summary company analytics:ARQT - Arcutis Corp
Original product of Arcutis

This indicator measures real cash flow from core operations before depreciation, taxes, and interest, allowing for an assessment of the business's ability to generate cash under market pressure. Analyzing operating accruals before depreciation is critical for Arcutis Biotherapeutics (ARQT), as it helps track the marketing effectiveness of new drugs and the risks of liquidity shortages resulting from high capital burn or low insurance coverage.

Competitor analysis for Arcutis Biotherapeutics

Operating income before deduction of amortization Krystal Biotech Corp. (KRYS)|APGE - Profit before payment of interest, taxes and amortization|VCEL - Operating profit EBITDA|ORKA: Operating profit EBITDA|SMTI - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization DBV Tech|Operating profit before amortization SLSN (Solesence Inc.)|Operating profit EBITDA DERM|Operating profit EBITDA fortebiorx.com (FBRX)|Profit before payment of interest, taxes and amortization Empro Group EMPG|Income before deduction of interest, taxes and amortization SLGL|Revive Pro Care - Operating profit EBITDA|Medicus Pharma Corp (MDCX) - Operating profit before deduction of amortization|VRCA (verrica.com) - Operating profit before deduction of amortization|Hoth Therapeutics (HOTH) - Operating profit EBITDA|Operating profit before deduction of amortization BFRI|VYNE (VYNE Therapeutics Inc) - Company profit before taxes, interest and amortization|Operating profit EBITDA SNOA|Operating income before deduction of amortization quoinpharma.com|Profit before payment of interest, taxes and amortization Azitra, Inc. AZTR|Operating income before deduction of amortization dermatarx.com (DRMA)|ELAB: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization RVNC (Revance Therapeutics Inc.)